LadRx Corporation Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 7/22/2026)
| Balance Sheet | Total Assets | 839,512.00 | ROE | – |
| Balance Sheet | Total Equity | -1,419,429.00 | ROA | – |
| Cashflow | Capital Expenditures | -766.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -1,310,333.00 | – | – |
| Cashflow | Operating Cash Flow | -1,310,333.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -3.21 | Div. Yield | – |
| Income | Net Income | -1,589,685.00 | P/E | – |
| Income | Shares Outstanding | 495,092.00 | P/B | – |
| Income | Total Revenue | 1,000.00 | P/S | – |
Ratios calculated on: –
Company Description
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company´s oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company´s tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.cytrx.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more